PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth while RVPH stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-57.23%
Negative gross profit growth while RVPH is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
5.53%
EBIT growth 1.25-1.5x RVPH's 4.38%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
5.53%
Operating income growth 1.25-1.5x RVPH's 4.38%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
5.62%
Positive net income growth while RVPH is negative. John Neff might see a big relative performance advantage.
13.79%
Positive EPS growth while RVPH is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.79%
Positive diluted EPS growth while RVPH is negative. John Neff might view this as a strong relative advantage in controlling dilution.
10.10%
Share reduction more than 1.5x RVPH's 39.46%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
10.10%
Diluted share reduction more than 1.5x RVPH's 39.46%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth under 50% of RVPH's 56.98%. Michael Burry might suspect questionable revenue recognition or rising costs.
17.73%
FCF growth under 50% of RVPH's 56.98%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
94.36%
OCF/share CAGR of 94.36% while RVPH is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
80.21%
3Y OCF/share CAGR of 80.21% while RVPH is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-551.14%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
94.20%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
81.22%
Positive short-term CAGR while RVPH is negative. John Neff would see a clear advantage in near-term profit trajectory.
1992.70%
Equity/share CAGR of 1992.70% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-67.70%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-15.48%
Negative 3Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Asset growth well under 50% of RVPH's 448.73%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.36%
Under 50% of RVPH's 448.05%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-16.56%
We’re deleveraging while RVPH stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-15.08%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.47%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.